Physician profile
Yousef Ibrahim
NPI 1528597861
$2,464.19
in general payments reported to CMS, 2019-2025
15 companies · $625 in 2025
The $625 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $266 · 2021: $343 · 2022: $318 · 2023: $297 · 2024: $503 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $742.47 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $339.32 | 2019-2021 | |
| Sight Sciences, INC. | $295.48 | 2023-2025 | Tearcare System, Omni Surgical System |
| Allergan, INC. | $161.27 | 2020-2022 | |
| Lkc Technologies, INC. | $137.56 | 2025 | |
| Bausch & Lomb Americas INC. | $130.24 | 2022-2025 | Infuse |
| Tarsus Pharmaceuticals, INC. | $121.70 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $96.14 | 2024 | |
| Novartis Pharmaceuticals Corporation | $94.21 | 2021 | |
| Abbvie INC. | $92.16 | 2024 | |
| Alcon Vision LLC | $90.18 | 2020 | |
| Shire North American Group INC | $88.61 | 2019 | |
| Dompe US, INC. | $32.13 | 2025 | Oxervate |
| Maculogix, INC. | $31.81 | 2020 | |
| Abb Con-Cise Optical Group LLC | $10.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousef Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.